/
Managing IBD Treatment of IBD Managing IBD Treatment of IBD

Managing IBD Treatment of IBD - PowerPoint Presentation

celsa-spraggs
celsa-spraggs . @celsa-spraggs
Follow
349 views
Uploaded On 2018-12-05

Managing IBD Treatment of IBD - PPT Presentation

Management of IBD Sprint or Marathon Challenges and Unmet Needs The Sprint When Sprinting Matters After the Sprint What Happens Next The Marathon LongTerm Remission Why Is It Important Colectomy Rates in Patients With UC Are Decreasing ID: 736622

therapy treatment ibd remission treatment therapy remission ibd clinical sprint marathon biological healing patient patients vedolizumab mucosal steroids individual

Share:

Link:

Embed:

Download Presentation from below link

Download Presentation The PPT/PDF document "Managing IBD Treatment of IBD" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.


Presentation Transcript

Slide1

Managing IBDSlide2

Treatment of IBDSlide3

Management of IBD

Sprint or Marathon?Slide4

Challenges and Unmet NeedsSlide5

The SprintSlide6

When Sprinting MattersSlide7

After the Sprint

What Happens Next?Slide8

The MarathonSlide9

Long-Term Remission

Why Is It Important?Slide10

Colectomy Rates in Patients With UC Are Decreasing

Swiss IBD Cohort StudySlide11

Long-Term Remission

Why Is It Important (cont)?Slide12

Steroids for the Treatment of CD

Benefit for the PatientSlide13

Steroids for the Treatment of UC

Symptomatic ControlSlide14

Thiopurines Prevent the Need for Surgery

in CDSlide15

Mucosal Healing as a Treatment GoalSlide16

Step Up, Top Down

Early Aggressive Therapy Causes Mucosal Healing in CDSlide17

Achievement of Mucosal Healing With Immunomodulators and Biological TherapySlide18

Benefits of Biological Agents for CDSlide19

Over Half of Patients Have a Primary or Secondary Loss of Response to Anti-TNF TherapiesSlide20

Lasting Clinical Remission With Vedolizumab

5-Year Cumulative Exposure DataSlide21

Sustained Clinical Remission Rates With Ustekinumab (2-Year Data)Slide22

Immunogenicity of Newer TherapiesSlide23

Best Practice for Managing the

Sprint vs MarathonSlide24

Treatment Options

Choosing a Biological Therapy for the MarathonSlide25

Evidence Beyond Clinical Trials on the Use of Vedolizumab and UstekinumabSlide26

VICTORY Consortium

Vedolizumab vs Anti-TNF Therapy (Propensity Score-Matched Analysis)Slide27

Key Considerations When Selecting a Therapy for an Individual PatientSlide28

Treatment PersistencySlide29

Targeting the Right Drug to the Individual Patient at the Right TimeSlide30

Monitoring Patients

Beyond Clinical SymptomsSlide31

Effective Infection Management May Improve Treatment PersistencySlide32

Concluding RemarksSlide33